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BACKGROUND: The effect of glycoengineering a membrane specific anti-carcinoembryonic antigen (CEA) (this paper uses the original
term CEA for the formally designated CEACAM5) antibody (PR1A3) on its ability to enhance killing of colorectal cancer (CRC) cell
lines by human immune effector cells was assessed. In vivo efficacy of the antibody was also tested.
METHODS: The antibody was modified using EBNA cells cotransfected with b-1,4-N-acetylglucosaminyltransferase III and the
humanised hPR1A3 antibody genes.
RESULTS: The resulting alteration of the Fc segment glycosylation pattern enhances the antibody’s binding affinity to the FcgRIIIa
receptor on human immune effector cells but does not alter the antibody’s binding capacity. Antibody-dependent cellular cytotoxicity
(ADCC) is inhibited in the presence of anti-FcgRIII blocking antibodies. This glycovariant of hPR1A3 enhances ADCC 10-fold relative
to the parent unmodified antibody using either unfractionated peripheral blood mononuclear or natural killer (NK) cells and
CEA-positive CRC cells as targets. NK cells are far more potent in eliciting ADCC than either freshly isolated monocytes or
granulocytes. Flow cytometry and automated fluorescent microscopy have been used to show that both versions of hPR1A3 can
induce antibody-dependent cellular phagocytosis (ADCP) by monocyte-derived macrophages. However, the glycovariant antibody
did not mediate enhanced ADCP. This may be explained by the relatively low expression of FcgRIIIa on cultured macrophages.
In vivo studies show the efficacy of glycoengineered humanised IgG1 PR1A3 in significantly improving survival in a CRC metastatic
murine model.
CONCLUSION: The greatly enhanced in vitro ADCC activity of the glycoengineered version of hPR1A3 is likely to be clinically beneficial.
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Antibodies are increasingly used for immunotherapy of cancers,
with over 200 currently in trials and 12 licensed for use in
treatment (Adams and Weiner, 2005; Carter, 2006; Reichert and
Valge-Archer, 2007). There are now three antibodies approved by
the US FDA for treatment of advanced colorectal cancer (CRC)
(Goldberg, 2005; Saltz et al, 2006; Reichert and Valge-Archer,
2007). The main potential advantages of this form of therapy lie in
their specificity, lesser side-effects and their ability to elicit a
tumour response by multiple mechanisms (Carter, 2006; Reichert
and Valge-Archer, 2007). The outcomes of early clinical trials
using murine unconjugated and radioconjugated monoclonal
antibodies for cancer treatment were disappointing (Goldenberg,
2002; Reichert and Valge-Archer, 2007) probably because of
immune responses to foreign proteins reducing serum half-lives,
and the delivery of inadequate radiation doses from the
radioconjugates to the tumour (Goldenberg, 2002; Sharkey and
Goldenberg, 2005; Reichert and Valge-Archer, 2007). Responses
were also severely limited by the attenuated ability of the Fc
segment of murine antibodies to interact with the relevant
receptors of the human immune system. These problems have
now been largely overcome by the development of technologies for
the production of chimeric, humanised and completely human
antibodies (Clynes, 2006).
Two lines of evidence support the importance of immune
function for naked antibody therapy. Firstly, Clynes et al (2000)
showed that antibody-based killing of xenografted and syngeneic
tumours was abrogated in FcgR knockout mice. This established
that the ability of antibodies to reduce tumour burden was greatly
reduced in the absence of immune cells expressing FcgRs.
Secondly, colorectal, lymphoma and breast cancer patients
carrying the polymorphic variants in the FcgRIIIa and FcgRIIa
genes that encode for high affinity binding receptors for the Fc
antibody segments, have the best clinical outcomes following
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santibody treatment (Weng and Levy, 2003; Zhang et al, 2007;
Musolino et al, 2008).
Responses to antibody therapy for solid cancers are so far
modest for cetuximab and trastuzumab monotherapy. Although
cetuximab in combination with irinotecan improves the response
rate from 10% to over 20% (Cunningham et al, 2004),
monotherapy response rates in haematological malignancies are
markedly higher than for solid cancers (McLaughlin et al, 1998).
This may be due to the increased surface area of haematological
tumours that is exposed to antibody binding and to NK cells
(Olszewski and Grossbard, 2004). Emphasis is now being placed on
techniques that ‘tune’ antibodies to make them more efficient at
harnessing the immune system for killing solid cancers. Thus,
technologies have been developed that engineer Fc antibody
segments to enhance their ability to elicit immune effector
functions, such as antibody-dependent cellular cytotoxicity
(ADCC). One approach uses protein engineering to modify the
Fc segment (Lazar et al, 2006). Another uses glycoform engineering,
which has been shown to improve in vitro ADCC by 10–100-fold
(Umana et al, 1999; Niwa et al, 2004b; Schuster et al, 2005). In this
study, we have used glycoengineering to enhance the immune
effector function of an antibody that we have shown earlier to kill
CRC-derived cell lines by ADCC (Conaghan et al, 2008).
The antibodies now used for the treatment of CRC target EGFR
and VEGF (Cunningham et al, 2004; Adams and Weiner, 2005;
Goldberg, 2005; Carter, 2006; Saltz et al, 2006) and only appear to
be effective in subsets of patients. Earlier work from our laboratory
has shown that the antibody PR1A3, which is specific for
membrane-bound carcinoembryonic antigen (CEA, formally
designated CEACAM5), elicits ADCC against CEA-positive CRC
cell lines even in the presence of super-physiological levels of free
CEA (Durbin and Bodmer, 1987; Durbin et al, 1994; Conaghan
et al, 2008). CEA is present on a high proportion of colorectal
cancers, in which it is accessible to intravenously administered
antibody, whereas in normal colorectal epithelium, due to the
apical localisation of the antigen, it is not (Granowska, 1993).
Radioconjugates targeting CEA have been used in early phase
clinical trials in CRC (Wong et al, 2004; Liersch et al, 2005), but
there is so far no unconjugated anti-CEA antibody licensed for
treatment (Blumenthal et al, 2008). The pre-clinical studies
reported here are directed at optimising PR1A3 for use in the
treatment of colorectal cancer. This antibody has been shown to
bind specifically to CEA in the B3-GPI domains. This epitope is at
the point CEA anchors into the membrane, and this presumably
explains why PR1A3 binds to membrane-bound CEA but not
soluble CEA (Durbin et al, 1994; Conaghan et al, 2008).
The three classes of FcgRs are expressed on NK cells, known to
be potent activators of ADCC (Schmitz et al, 2002; Lazar et al,
2006; Conaghan et al, 2008), and on monocytes and granulocytes,
which have also been identified as having at least some potential
for antibody-dependent killing of target cells, for example, by
antibody-dependent cellular phagocytosis (ADCP) (Munn et al,
1991; Huls et al, 1999; Dhodapkar et al, 2005; Lazar et al, 2006;
Karagiannis et al, 2007; McEarchern et al, 2007). We describe here
a modified phagocytosis assay, based on that developed by Munn
et al (1991), and its application to the in vitro testing of the ability
of humanised and glycoengineered PR1A3 to kill CRC-derived cell
lines. We also present in vivo data that shows the efficacy of PR1A3
as a therapeutic agent in a mouse xenograft model.
MATERIALS AND METHODS
Cell lines
The SKCO-1 (from ATCC), LS174T (from BH Tom, NW
University, Chicago), LoVo (from ATCC), HCT116 (from ATCC)
and MKN45 (from Cell Services LIF, CRUK, London, UK) cell lines
were cultured as described (Conaghan et al, 2008). For cytotoxicity
and phagocytosis assays, cells were suspended in 2% RPMI 1640
medium with 1% glutamine and 10% FCS (RPMI complete medium).
Antibodies
PR1A3 The original murine IgG1k monoclonal antibody to CEA
(Richman and Bodmer, 1987) was humanized by Stewart et al
(1999). Murine (mPR1A3, IgG1) and unmodified humanized
(uhPR1A3, IgG1) antibodies were acquired from the Biotherapeu-
tics Development Unit, Clare Hall, CRUK, London, UK. Murine
IgG2a PR1A3 (mPR1A3, IgG2a) and a glycoengineered version of
re-derived humanised IgG1 PR1A3 (ghPRA1A3, IgG1) were made
by joining the variable region of PR1A3 to murine IgG2a and the
complementarity determining regions of PR1A3 to human IgG1
variable regions, respectively (Jones et al, 1986). Glycoengineering
was as described (Umana et al, 1999; Schuster et al, 2005). Briefly,
vectors containing IgG heavy and light chains, and b(1,4)-N-
acetylglucosaminyltransferase-III (GnT-III), were transfected into
EBNA cells. The enzyme modifies the N-glycosylation pattern at
Asn-297 of the IgG heavy chain resulting in a high degree of
bisected, afucosylated oligosaccharides (Umana et al, 1999;
Schuster et al, 2005; Ferrara et al, 2006), which has been shown
earlier to increase the affinity to FcgRIIIa (Ferrara et al, 2006).
The modified antibody was purified from culture supernatants
using Protein-A, cation-exchange chromatography and subsequent
size-exclusion chromatography.
SM3E This is a humanised IgG1 antibody that binds with
extremely high affinity (Kd¼20pM) to both soluble and
membrane-bound CEA (Graff et al, 2004). A glycoengineered
variant was generated using the methods described above.
Blocking antibodies Purified IgG1 anti-CD16 (FcgIII) (clone 3G8,
which is unable to distinguish between FcgRIIIa and FcgRIIIb),
purified IgG1 anti-CD64 (clone 10.1), and Fab2 fragments targeting
CD16 (clone 3G8), CD32 (FcgII, clone 7.3) and CD64 (FcgII, clone
10.1) were purchased from Ancell Corp, Bayport, MN, USA.
Purified IgG2b anti-CD32 (clone IV.3) was purchased from
Stemcell Technologies (Vancouver, Canada).
FITC-conjugated murine anti-human IgG (clone G18-145),
CD3-FITC, CD11b-PE, CD14-PE, CD15-FITC, CD16-PE, CD19-PE,
CD32-PE, CD45-PE, CD56-APC, CD64-FITC, IgG1-FITC (isotype
control), IgG1-PE (isotype control) and IgG1-APC (isotype
control) were obtained from BD Biosciences, Oxford, UK. Anti-
HLA class II (DA-2) was obtained from Monoclonal Antibody
Services, CRUK (Brodsky et al, 1979).
Isolation of immune effector cells
Peripheral blood mononuclear cells (PBMCs) were isolated from
healthy laboratory volunteers, having taken informed consent, or
from buffy coats obtained from single donors (National Blood
Service, Bristol, UK). The Rosettesep Human NK isolation cocktail
(Stemcell Technologies) was used to obtain an enriched population
of human NK cells from blood, as described (Roda et al, 2006).
Granulocytes were separated using One-step Polymorph (Accurate
Chemical and Scientific Corp, Westbury, NY, USA). Monocytes
were enriched from blood using the Rosettesep Human Monocyte
Enrichment Cocktail (Stemcell Technologies). Purification
was verified by phenotypic analysis of surface markers
(See Supplementary Materials for details).
Flow cytometric analysis to compare uhPR1A3 and
ghPR1A3 binding to membrane-bound CEA
Cells from SKCO-1, a high CEA expressing CRC line used as target,
were incubated in varying concentrations of uhPR1A3 or ghPR1A3
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 1), and with anti-human IgG-FITC as secondary
antibody. The cells were then washed once with FACS buffer
(PBSA, 1% FCS, 1% Sodium Azide) and the supernatant removed
before resuspending in 2% paraformaldehyde in PBSA. FACS
analysis was carried out using a FACS Calibur Flow cytometer.
Fluorescence-based EuTDA cytotoxicity assay
As described (Conaghan et al, 2008), a fluorescent probe, BATDA
(Blomberg et al, 1996) (Perkin Elmer, Boston, MA, USA), was used
to label target cells. PBMCs, NK cells, monocytes and granulocytes
were used as effectors with varying effector:target cell ratios and
concentrations of antibodies. After appropriate incubation, super-
natant was added to Europium in 96-well plates and the resulting
fluorescence read in a time-resolved fluorometer.
The EuTDA assay was used to compare the ADCC activity of
mPRA13 IgG1, mPR1A3 IgG2a and uhPR1A3 IgG1 on SKCO-1
cells, using antibody at a final concentration of 20mgml
 1 and
either PBMCs or NK cells as effectors.
The effect of blocking FcgRs I, II and III using Fab2 or IgG
antibodies was assessed using the EuTDA to measure uhPR1A3
mediated ADCC of SKCO-1. PBMC and enriched NK cells were
used as effectors. Murine IgG prostate membrane specific antigen
(PMSA, provided by Robert Vessella, University of Washington)
was used as an isotype murine control.
The relative ability of PBMCs, NK cells, monocytes and
granulocytes, enriched, as described earlier, to elicit ADCC was
assessed using the EuTDA assay with uhPR1A3.
Monocyte-derived macrophages for phagocytosis assays
Enriched monocytes were cultured on Lumox Petraperm Plates
(Greiner, Bio-One, North America, Monroe, NC, USA), for 8–12
days at 371 in a 5% CO2 incubator, in X-VIVO 15 medium
(BioWhittaker, Walkersville, MD, USA), supplemented with M-CSF,
GM-CSF and gIFN (Peprotech, UK) (see Supplementary Materials for
details). Target cells (SKCO-1) were labelled with CellTracker Green
CMFDA (Invitrogen, San Diego, CA, USA). Free label was washed off
before incubation with varying concentrations of uhPR1A3 or
ghPR1A3 (0.1 –10mgml
 1). Effector monocyte-derived macrophages
were added (3:1–8:1 effector:target ratio), the cells were incubated
for 1h at 371 and analysed using FACS Calibur to measure ADCP.
An alternative ADCP assay was developed using an automated
microscope (Ikoniscope, Ikonisys, New Haven, CT, USA) (Ntouroupi
et al, 2008). Target cells and macrophages, stained as described
above, were deposited on to a poly-l-lysine coated slide, fixed with
2% formaldehyde. The slides were washed with PBS containing
Tween (PBS-Tween), covered with blocking solution and Goat
anti-mouse–HRP (1:100 dilution in blocking solution) added as a
secondary antibody. The slides were washed with PBS-Tween,
before adding Tyramide-647 (1:100 dilution).
Phagocytosis events were detected using the Ikoniscope imaging
system (Ntouroupi et al, 2008). Slides are first scanned at low
magnification ( 10) to detect green label and then revisited at
high magnification ( 100) to identify red labelled macrophages
with ‘engulfed’ green targets.
In vivo testing of PR1A3
Six to 12-week-old SCID/Beige mice were used for animal
experiments. All experiments were performed after ethical
approval from the Swiss Veterinary Office. LS174T cells were
maintained in DMEM medium with 1% glutamine and 10% FCS
(E4 complete medium). A murine model for CRC tumours was set
up by intra-splenic injection of LS174T (3 10
6 cells per mouse)
under aseptic conditions (day 0). This resulted in the development
of liver metastasis. Passive antibody protection was measured by
comparing the survival of mice (n¼10 for each group) after
intravenous injection of either glycoengineered humanised IgG1
PR1A3, or glycoengineered high affinity IgG1 anti-CEA antibody
(clone SM3E,) or vehicle PBS control. The SM3E antibody, unlike
PR1A3, is not membrane CEA specific. Antibody injections were
performed at days 7, 14 and 21 with a treatment dose of 25mgkg
 1
of bodyweight of mouse. Termination criteria were in accordance
with the Swiss Veterinary Office.
ADCC and ADCP data analysis
Percentage cell lysis in the cytotoxicity assays was calculated as
[experimental release background release]/[maximum relea-
se background release] 100. Antibody-dependent (specific)
lysis was calculated as [experimental release antibody-indepen-
dent release]/[maximum release antibody-independent release]
 100. The standard error of the mean of multiple experiments
was calculated using Graphpad Prism software, San Diego, CA,
USA. Percentage cell phagocytosis was calculated using the
formula: number of dual-stain positive target cells (cells engulfed
by macrophages) divided by the total number of target cells.
Standard normal distribution tests were performed to test the
significance of differences found.
RESULTS
The binding of uhPR1A3 and ghPR1A3 to SKCO-1, based on FACS
analysis, was similar over a wide range of concentrations (0.001–
100mgml
 1) (Figure 1; see Supplementary Figure S1). Glyco-
engineering the Fc segment of PR1A3 has, therefore, no effect on
the binding efficiency of the antibody to its epitope on a CEA-
expressing CRC line. The affinity of PR1A3 Fab for cell-bound CEA
is approximately 10nM.
The ADCC mediated activities of mPR1A3IgG1, mPR1A3IgG2a
and uhPR1A3IgG1, using human effector cells and SKCO-1 as
targets, are illustrated in Figure 2A and B. The data show that
uhPR1A3IgG1 kills much more actively than either mPR1A3IgG1
or mPR1A3IgG2a. PR1A3 does not mediate any killing in the
absence of immune cells (data not shown). These data confirm that
hPR1A3 mediated killing depends on the appropriate Fc–FcgR
interaction.
Using enriched NK cells as effectors and SKCO-1 as targets, the
effects on hPR1A3 mediated ADCC of blocking with Fab2 and IgG
antibodies against the three known human classes of FcgRs, CD64
(FcgRI), CD32 (FcgRII) and CD16 (FcgRIII), are shown in Figure 3.
CD16 Fab2 blocks the ADCC somewhat more than CD16 IgG,
whereas CD32 Fab2 had no significant effect. However, CD32 IgG
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Figure 1 Comparison of the binding of unmodified humanised IgG1
PR1A3 (uhPR1A3) and glycoengineered IgG1 PR1A3 (ghPR1A3) to the
high CEA expressing cell line SKCO-1. Mean fluorescent intensities, based
on flow cytometric analysis, of uhPR1A3 and ghPR1A3 at different antibody
concentrations. Sigmoidal dose–response curves are fitted using Prism
Graphpad software (goodness of fit, R
240.98).
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s(clone IV.3) was as effective, if not more so, than CD16 IgG in
inhibiting both ADCC and antibody-independent killing. Neither
CD64 Fab2 nor IgG had any significant effect, whereas PMSA
antibody, used as a non-specific blocking control, showed the
absence of non-specific competition for FcgRs on effector cells.
NK cells, which predominantly express FcgRIIIa, mediate ADCC
at much lower effector:target ratios than whole PBMC (Schmitz
et al, 2002; Lazar et al, 2006; Conaghan et al, 2008). Monocytes,
however, express all three classes of FcgRs on their surface, and
granulocytes express both FcgRIIa and IIIb. Thus, both these cells
types might be expected to contribute to ADCC. NK cells,
monocytes and granulocytes were therefore compared as effectors
for ADCC using the EuTDA assay, as shown in Figure 4. NK cells,
defined as CD3 /CD56þ/CD16þ, using CD56 (x-axis) and CD16
(y-axis) antibodies (Figure 4A; left panel before, and right panel
after sorting) elicited significant ADCC with 20mgml
 1 of
uhPRA1A3 IgG1 and SKCO-1 as targets even at effector to
target ratios of 10:1 (Figure 4B). Neither, monocytes, defined as
CD3 /CD11bþ/CD14þ/CD15 /CD16low/CD19 /CD32þ/CD45þ/
CD56 /CD64þ (Figure 4C; left panel before, and right panel after
sorting using anti CD14 (x-axis, stain intensity; y-axis, event
frequency), nor granulocytes, defined as CD3 /CD14 /CD15þ/
CD16þ/CD19 /CD56  (Figure 4E after enrichment using anti-
CD15) showed any evidence of ADCC even at effector:target ratios
of up to 40:1 (Figure 4D and F).
Figure 5A shows that glycoengineered antibody, ghPR1A3,
elicits ADCC at much lower concentrations than the unmodified
form. Thus, just 1mgml
 1 of ghPR1A3 kills over 40% of SKCO-1
target cells, using unfractionated PBMC as effectors, whereas
1mgml
 1 of uhPR1A3 kills only about 10% of the targets,
suggesting 10–100-fold increased effectiveness of the glycoengi-
neered antibody. Figure 5B shows that 1mgml
 1 of ghPR1A3 is
significantly more effective at mediating killing than is 1mgml
 1
uhPR1A3 over a range of effector to target ratios from 25:1 to
100:1, again using PBMC as effectors. Figure 5C shows that the
difference between the killing efficiency of ghPR1A3 and uhPR1A3
is similar using effector cells from three different PBMC donors
whereas Figure 5D shows that using enriched human NK cells as
effectors, ghPR1A3 is significantly more effective than uhPR1A3
at killing SKCO-1 cells over a range of concentrations
(1–20mgml
 1), as expected if NK cells are the main cell type
mediating ADCC in PBMC. Figure 5E and F shows that ghPR1A3
was also significantly more effective than uhPR1A3 in killing the
intermediate CEA-expressing cancer cell lines MKN45, and,
particularly, LoVo, the latter even at an effector:target ratio of
25:1. As expected, no enhancement was seen for HCT116, a cell
line that does not express CEA (data not shown).
To investigate macrophage-based ADCP (Munn et al, 1991;
Watanabe et al, 1999; Lazar et al, 2006; McEarchern et al, 2007),
monocytes were cultured to give rise to macrophages, which
by FACS analysis were shown to be negative for CD3, CD15, CD19
and CD56, positive for CD11b, CD14, CD32, CD64 and HLA class II
and weakly positive for CD16 (see Supplementary Figure S2a).
The cultured monocytes adhere to the bottom of the plates and have
an enlarged granular appearance, as expected for macrophages
(see Supplementary Figure S2b). Freshly harvested macrophages
were incubated with green CMFDA labelled SKCO-1, and a range
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Figure 3 Effect of FcgR blocking on unmodified humanised PR1A3-
induced ADCC, using anti-CD16, 32 and 64 Fab2 or IgG. SKCO-1 was
used as the target and NK cells as the effectors (effector:target
ratio¼8:1). The P-values are for the significance of the differences
between the result using hIgG1PR1A3 and no blocking antibody, based on
t-tests.
−10
0
10
20
30
40
50
60
70
80
90
100
P=0.0359
P=0.0051
1 2 4 8 16 32 64 –10
0
10
20
30
40
50
60
70
80
90
100 mIgG2a
mIgG1
hIgG1
[PR1A3] g ml–1
Target/effector
Murine IgG1 PR1A3
Murine IgG2a PR1A3
Humanised IgG1 PR1A3
%
 
S
p
e
c
i
f
i
c
 
l
y
s
i
s
%
 
C
e
l
l
 
l
y
s
i
s
Figure 2 (A) Comparison of the ADCC activity of PR1A3 antibodies
with differing Fc portions (murine IgG1, murine IgG2a and humanised
IgG1). PBMC were used as effectors and SKCO-1 used as the target
(100:1 effector:target ratio). Antibodies were used at a final concentration
of 10mgml
 1. The control was targets and effectors with no antibody. The
P-values are for the significance of the differences between controls and the
hIgG1PR1A3 results, based on t-tests. (B) Comparison of the ADCC
activity of PR1A3 antibodies with differing Fc portions (murine IgG1, murine
IgG2a and humanised IgG1) over a range of antibody concentrations from
1t o5 0 mgml
 1. PBMC were used as effectors and SKCO-1 as target
(50:1, effector:target ratio).
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sof antibody concentrations using macrophage:target ratios from
3:1 to 8:1. A representative FACS analysis of the mixture of
macrophages and target SKCO-1 cells after 1-h at 371 in the
presence of an isotype control (PMSA), uhPR1A3 and ghPR1A3
antibodies (5.0mgml
 1) is shown in Figure 6A. The green-labelled
target cells are in the right lower quadrant and the effectors,
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Figure 4 Comparative ADCC activity of different cell types from a single healthy donor. (A) FACS analysis dot plot showing the enrichment of NK cells
from PBMC (x-axis, CD56; y-axis, CD16) pre (left-hand dot pot) and post (right-hand dot plot) sorting. (B) NK ADCC activity. Graph of NK ADCC activity
against SKCO-1 in the absence and presence of 20mgml
 1 of hPR1A3 at different effector:target ratios (x-axis) vs % cell lysis (y-axis). (C) FACS analysis
plot showing the enrichment of monocytes from PBMC (x-axis, CD14 intensity; y-axis, number of events)- pre (left-hand histogram plot) and post (right-
hand histogram plot) sorting. Grey line presents staining using CD14 antibody-PE; dark line represents staining with isotype antibody control-PE. (D)
Monocyte ADCC activity. Graph of monocyte ADCC activity against SKCO-1, in the absence and presence of 20mgml
 1 of hPR1A3, at different
effector:target ratios (x-axis) vs % cell lysis (y-axis). (E) FACS analysis plot showing the enrichment of granulocytes from fresh blood after sorting (x-axis,
CD15 intensity; y-axis, frequency of events). Grey line presents staining using CD15 antibody-FITC; dark line represents staining with isotype antibody
control-FITC. (F) Granulocyte ADCC activity. Graph of granulocyte ADCC activity against SKCO-1 in the absence and presence of 20mgml
 1 of hPR1A3,
at different effector:target ratios (x-axis) vs % cell lysis (y-axis).
Figure 5 (A) Comparison of ADCC activity of glycoform engineered humanised PR1A3 (ghPR1A3) with unmodified humanised PR1A3 (uhPR1A3) using
PBMC. SKCO-1 were used as targets. Effector:target ratio used was 50:1 (x-axis, concentration of PR1A3 used; y-axis, % specific lysis). (B) Comparison of
ADCC activity of ghPR1A3 with uhPR1A3 at different effector:target ratios and a fixed antibody concentration of 1mgml
 1 for both variants. The target
cells were SKCO-1 and effectors PBMCs from fresh blood (x-axis, effector:target ratio used; y-axis, % specific lysis). (C) Comparison of ADCC activity of
ghPR1A3 with uhPR1A3, using PBMC from three separate donors. SKCO-1 (a high CEA expressing cell line) were the targets. Effector:target ratio was
50:1 (x-axis, concentration of PR1A3 used; y-axis, % specific lysis). (D) Comparison of ADCC activity of ghPR1A3 with uhPR1A3 using human NK cells and
SKCO-1 as targets (x-axis, concentration of PR1A3 used; y-axis, % specific lysis). Effector:target ratio used was 10:1. (E) Comparison of ADCC activity
of ghPR1A3 with uhPR1A3, using PBMC as effectors, on MKN45 (an intermediate CEA expressing cell line) as the targets. Effector:target ratio was 50:1
(x-axis, log concentration of PR1A3 used; y-axis, % specific lysis). (F) Comparison of ADCC activity of ghPR1A3 with uhPR1A3, using PBMC as effectors
on LoVo (an intermediate CEA expressing cell line) as the targets. Effector:target ratio was either 25:1 or 50:1 (x-axis, log concentration of PR1A3 used;
y-axis, % specific lysis).
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slabelled with PE conjugated anti-CD11b/CD14, in the left upper
quadrant of the dot plots. After one hour’s culture in the presence
of either uhPR1A3 or ghPR1A3 there were substantial numbers of
red and green positive signals in the upper right quadrant,
presumably representing macrophages containing engulfed target
cells, in contrast to the results for the PMSA control (Figure 6A).
The proportion of such signals is essentially the same for both
uhPR1A3 and ghPR1A3, and is concentration dependent, as shown
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Figure 6 (A) Flow cytometric analysis of ADCP. SKCO-1 target cells were stained green with CMFDA and are present in the right lower quadrant of the
dot plots. Macrophages were stained with anti-CD11b and CD14 conjugated with PE. They appear in the left upper quadrant of the dot plots. The left hand
dot plot is from a representative 1-h culture of macrophages and target cells (SKCO-1) in the presence of IgG isotype control. The middle and right plots are
from representative 1-h cultures of macrophages and target cells in the presence of uhPR1A3 and ghPR1A3, respectively (5mgml
 1). The effector:target
ratio used was 5:1. (B) Effect of increasing concentrations of uhPR1A3 and ghPR1A3 on phagocytosis. Tumour targets were pre-incubated with an isotype
control antibody (IgG, 10mgml
 1) or the variants of hPR1A3 at concentrations of 0.1–10mgml
 1. ADCP was determined by flow cytometric analysis as the
percentage of targets in the upper right hand quadrant (see Figure 6C). The four graphs represent responses from four separate donors. (C) Effect of FcgR
blocking on ADCP. Flow cytometry was used to calculate the percentage of tumour cell engulfment by cultured macrophages in the presence of 10mgml
 1
of uhPR1A3. Fab2 fragments were used to block either FcgR I (CD64), FcgR II (CD32) or FcgR III (CD16) (each antibody concentration was1mgml
 1).
The effector:target ratio used was 3:1, and the targets were SKCO-1. (D) Fluorescent images of macrophages phagocytosing SKCO-1 using the Ikoniscope.
The macrophages (red) have been stained with anti-CD14 and anti-CD11b primary antibodies followed by goat anti-mouse-HRP and Tyramide 647. The
target cell line (SKCO-1) was stained green with CMFDA (Celltracker probe). The left hand panels show microscope composite images viewed with FITC
(green), Cy5 (for tyramide 647) and DAPI (blue) channels. The second, third and fourth panel column show the same cells viewed separately with the DAPI,
green and Cy5 channels. Each represents a different phagocytic event.
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sin Figure 6B for four different donors. This indicates that, in
contrast to ADCC, glycoengineering does not enhance ADCP. The
apparent lower level of expression of FcgRIII (CD16) as compared
with FcgRII (CD32) (see Supplementary Figure S2a) suggests that
the density of surface membrane CD16 on macrophages may not
be enough for glycoengineering of PR1A3 to enhanced ADCP.
The effects on FACS assayed ADCP of blocking with Fab2
fragments each of three classes of FcgRs receptor are shown in
Figure 6C. Blocking FcgRII (CD32) or FcgRIII (CD16) reduced
ADCP to some extent, whereas blocking FcgRI (CD64) had no
effect. This indicates that both CD16 and CD32 are involved in
ADCP, whereas previously only CD32 was thought to be mainly
involved (Richards et al, 2008). The CD16 antibody (3G8 clone)
used for blocking does not, however, distinguish between FcgRIIIa
and FcgRIIIb. This suggests that the lack of an effect of
glycoengineering on ADCP may be due to a lower concentration
of FcgRIIIa than FcgRIIIb on macrophages, and the fact that the
glycoengineering only enhances the binding to FcgRIIIa.
For the Ikoniscope-based ADCP assay target, SKCO-1 cells were
labelled green with CMFDA and the macrophages red by
combining anti-CD11a and anti-CD14 as primary antibodies
followed by goat anti-mouse HRP and Tyramide 647 staining.
Examples of fluorescent images of macrophages clearly engulfing
the target cells, are shown in Figure 6D. In some cases, the
macrophages clearly contain two nuclei, one of which is associated
with the green stain of a target cell. Using the Ikoniscope it is
therefore possible to count, separately, engulfed targets, conju-
gated targets, free targets and macrophages. Table 1 shows the
relative percentage of presumed phagocytosis events seen with
the FACS analysis compared with the percentage of confirmed
phagocytosis events and percentage of conjugating events seen
with the Ikoniscope. Combining engulfed and conjugated targets,
as estimated using the Ikoniscope, there is reasonable agreement
with the FACS analysis, which cannot distinguish simple attach-
ment from actual engulfment. This suggests that the Ikoniscope-
based ADCP assay gives more accurate results than that based on
FACS analysis, which is the basis of previous publications
reporting ADCP (Munn et al, 1991; Huls et al, 1999; Akewanlop
et al, 2001; Lazar et al, 2006; McEarchern et al, 2007). The
quantitative data of Table 1 also suggest that the glycoengineered
Composite Dapi/nuclei Green/CRC Cy5/macrophage D
Figure 6 Continued.
Table 1 Comparison of the ability of different hPR1A3 variants to elicit ADCP using the Ikoniscope
PMSA control ghPR1A3 unPR1A3
Total targets 1336.00 1284.00 1428.00
Targets engulfed by macrophages 27.00 122.00 213.00
Conjugates between targets and macrophages 38.00 79.00 116.00
% of targets engulfed 2.02 9.50 14.92
% of targets conjugated 2.84 6.15 8.12
% phagocytosis+% conjugated 4.87 15.65 23.04
% ADCP using FACS 10.22 22.11 28.56
The number of target cells that were engulfed by macrophages was counted directly using the Ikoniscope. Targets that were conjugated to macrophages were defined as having
cell-to-cell membrane contact but no envelopment. Targets and macrophages could readily be identified separately. The percentages of engulfed and conjugated cells are
compared with the percentage of targets classified as having undergone ADCP using FACS analysis of the same preparation of cells.
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santibody may be slightly less effective in eliciting ADCP than the
unmodified antibody.
To test its in vivo efficacy, glycoengineered humanised PR1A3
(IgG1 subclass) was used in a murine CRC model consisting of
LS174T induced-liver metastasis. The engineered PR1A3 antibody
resulted in significantly improved survival of animals when
compared with the vehicle PBS control (see Figure 7). A high
affinity IgG1 anti-CEA antibody (SM3E) was also used and was
found to prolong survival. This antibody is more effective at
eliciting in vitro ADCC when compared with PR1A3. However,
despite its considerably lower affinity for CEA (Kd,1 0n M vs 20pM),
ghPR1A3 was found to be equally effective at prolonging survival
when compared with SM3E. These data show that passive
immunisation of glycoengineered humanised IgG1 PR1A3 is
effective in prolonging survival in a CEA-positive CRC metastatic
tumour model.
DISCUSSION
Antibody engineering to enhance ADCC can be achieved either by
altering the amino acid structure of the Fc backbone or by
modifying the carbohydrate structures at the hinge region
(glycoengineering) to improve the binding affinity to Fcg receptors
(Umana et al, 1999; Niwa et al, 2004b; Lazar et al, 2006). Three
glycoengineering approaches have been used (i) over expression of
the enzyme GntIII in the antibody producing cells, which results in
the Fc segment containing an increase in bisected non-fucosylated
oligosaccharides, (ii) producing antibody in CHO cells that
lack the transferase enzyme involved in core-fucosylation and
(iii) using siRNA to knockdown fucosyl transferase activity. Over
expression of GntIII has been used successfully to increase the
in vitro ADCC potency of antibodies IGN311 (Lewis Y-specific)
and chCE7 (anti-neuroblastoma) (Umana et al, 1999; Schuster
et al, 2005). Using this technique, we have shown that the ADCC
activity of the humanised IgG1 anti-CEA antibody PR1A3 can be
increased more than 10-fold. This effect is seen in both
intermediate and high expressing CEA cell lines. The level of
enhancement may be pronounced even at low effector:target
ratios in intermediate expressing CEA cell lines. This underlines
the potency of ghPR1A3, which may be particularly relevant
considering that antibody penetration into tumours may limit
therapeutic capacity. Therefore, it is of paramount importance to
show efficient antibody killing by human effector cells. This ADCC
activity is still dependent on CD16 (FcgRIIIa) on the NK cells, as
shown by Fab2 anti-CD16 blocking and enhanced ADCC of
ghPR1A3 over uhPR1A3 in the presence of enriched NK cells. The
improved ADCC activity of the glycoengineered antibody is
achieved without affecting PR1A3’s binding activity, leaving it
membrane specific, as described earlier (Durbin et al, 1994;
Stewart et al, 1999). This is an important property of PR1A3, given
the finding that soluble CEA can accumulate in lymph nodes and
lead to false positive detection of cancers in lymph nodes when
using other anti-CEA antibodies for immunoscintigraphy
(Granowska et al, 1989). In contrast to NK cells, neither freshly
isolated granulocytes nor monocytes show any significant ADCC
activity at comparable antibody concentrations even with high
effector:target ratios. The lack of monocyte-based ADCC activity
may be due to the low level of CD16 found in our preparations. We
have shown, however, using two different assays, that macrophages
kill target tumour cells in vitro by ADCP. Both of these mechanisms
are therefore likely to have a significant function in in vivo patient
responses to naked antibody therapy. Glycoengineering substan-
tially improves antibody PR1A3’s NK cell mediated ADCC activity,
but apparently has no effect on in vitro macrophage-based ADCP.
This suggests that the FcgRIIIa receptor is not the effective Fc
receptor on macrophages for ADCP and opens up the possibility of
alternative engineering of antibodies to enhance their ADCP
activity (Richards et al, 2008). However, the expression of FcgRs
on macrophages is dependent on the cytokines in the tumour
microenvironment, and so the in vitro assay may not reflect the in
vivo situation, and this needs further investigation. The in vivo
data presented here show that glycoengineered humanised IgG1
PR1A3 is effective in prolonging survival in a murine CRC
metastatic model. This is thought to work by interaction between
the Fc segment of the antibody and FcgRIV, the murine homologue
of human FcgRIIIa. These latter receptors are found on macro-
phages and granulocytes in mice, emphasising the subtle
differences between the mouse and human immune systems.
Interestingly, despite the hugely lower affinity for CEA of PR1A3 as
compared with SM3E, the improvement in survival was at least as
great, if not greater with PR1A3 as with SM3E. This contrasts to the
findings in vitro, in which glycoengineered SM3E has a much
higher ADCC capacity than PR1A3. The in vivo finding may be
explained by the distinctive specificity of PR1A3 for binding to
membrane-bound CEA and scavenging of SM3E by shed CEA.
Binding to soluble CEA, leading to sequestration of antibody–
antigen complexes away from the tumour, is a major obstacle for
any potential therapeutic anti-CEA antibody.
The glycoengineered variant antibodies have been shown to
have substantially improved binding to the lower affinity FcgRIIIa
receptor polymorphic variants, which have phenylalanine instead
of valine at amino acid position 158 (Ferrara et al, 2006).
In addition, the carbohydrate residue at Asn-162 of FcgRIIIa has
also been shown to have an important function in the binding of
glycoengineered Fc segments, such that its absence leads to greatly
attenuated affinity for these antibody variants (Ferrara et al, 2006).
As only 10–15% of patients have the high affinity FcgRIIIa
receptor polymorphic variants, use of the glycoengineered variant
antibody should make this therapy accessible to all patients,
whatever their genetic constitution with respect to these FcgRIIIa
receptor polymorphic variants (Cartron et al, 2002; Weng and
Levy, 2003; Niwa et al, 2004a,b; Schuster et al, 2005).
Earlier studies on macrophage mediated in vitro phagocytosis
have relied heavily on FACS analysis using PKH lipid linkers to
stain target cells (Munn et al, 1991; Huls et al, 1999; Akewanlop
et al, 2001; Lazar et al, 2006; McEarchern et al, 2007; Richards et al,
2008). These linkers can, however, diffuse non-specifically from
cell to cell, giving rise to false positive signals and thus limiting
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Figure 7 In vivo testing of glycoengineered PR1A3. Survival was
measured in SCID/beige mice treated with either glycomodified humanised
IgG1 PR1A3 (n), glycomodified IgG1 SM3E (&) or vehicle control (})
(n¼10 in each treatment group). Y-axis represents % survival and x-axis
represents number of days after injection of tumour. Both SM3E and
PR1A3 increased survival significantly when compared with the vehicle
control (Po0.05). There was no significant difference in survival between
SM3E and PR1A3 treatments.
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stheir use for phagocytosis assays. The use of a cytoplasmic stain,
coupled with the Ikoniscope, shows unequivocally that cultured
macrophages are able to phagocytose tumour cells in the presence
of PR1A3, and enables satisfactory quantitation of the ADCP assay.
The low relative ADCC activity of the murine IgG2a or IgG1 Fc
domains on human cells is consistent with the dependence of
ADCC on the specificity of the binding of the Fc portion of an
antibody to the relevant Fc receptor (FcgRIIIa) on NK cells. This
may, in part, explain the poor results obtained in early oncology
trials using naked murine monoclonal antibodies. On the basis of
the blocking experiments with Fab2 of CD32 and CD64, these
receptors have little if any role in NK mediated ADCC. However,
intact anti-CD32 antibody (clone IV.3, IgG2b), in contrast to the
Fab2 fragment (clone 7.3), is as at least as potent as intact anti-
CD16 in inhibiting both ADCC and antibody-independent killing.
This may be explained by low levels of CD32c on NK cells (present
in 40% of donors; Metes et al, 1998) that may lead to self-killing or
a secondary cross-linking effect between FcgRs.
NK-based ADCC and macrophage-based ADCP are the most
likely mechanisms for naked anti-CEA antibody therapy (Munn
et al, 1991; Huls et al, 1999; Watanabe et al, 1999; Akewanlop et al,
2001; McEarchern et al, 2007), as there is no obvious basis for a
functional blocking effect involving CEA. In addition, macro-
phages are known to be potent antigen-presenting cells and so,
following antibody stimulated engulfment of whole tumour cells,
macrophages may digest the engulfed cells and then re-present
peptide fragments to T cells. This may then enable the activation of
the adaptive immune system against tumour cell products (Adams
and Weiner, 2005; Carter, 2006). It is also likely that dendritic cells,
which are super antigen presenters and express FcgRs, are
stimulated by antibodies to engulf target cells, which would
significantly enhance their ability to present tumour antigens to
the adaptive immune system (Kalergis and Ravetch, 2002; Benitez-
Ribas et al, 2006; Melief, 2008). Glycoengineering and other
modifications of antibodies to enhance their immune effector
functions appear, therefore, to be a most effective way to improve
the efficacy of naked antibody therapy by a variety of mechanisms.
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